Evidence map›Paper›PMID 40481442›Full record

ArticleBMC cancer2025

Safety and efficacy of systemic chemotherapy plus PD-1 inhibitor in combination with intravenous or intraperitoneal bevacizumab in gastric cancer with peritoneal metastasis.

Yuxi Ma, Yuting Li, Zhenyu Lin, Jing Wang, Jianli Hu, Hongli Liu, Yali Yang, Junli Liu, Tao Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yuxi MaCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 109 Machang Road, Jianghan District, Wuhan, 430022, China.
Yuting LiCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 109 Machang Road, Jianghan District, Wuhan, 430022, China.
Zhenyu LinCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 109 Machang Road, Jianghan District, Wuhan, 430022, China.
Jing WangCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 109 Machang Road, Jianghan District, Wuhan, 430022, China.
Jianli HuCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 109 Machang Road, Jianghan District, Wuhan, 430022, China.
Hongli LiuCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 109 Machang Road, Jianghan District, Wuhan, 430022, China.
Yali YangCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 109 Machang Road, Jianghan District, Wuhan, 430022, China.
Junli LiuCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 109 Machang Road, Jianghan District, Wuhan, 430022, China. junli78@foxmail.com.
Tao ZhangCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 109 Machang Road, Jianghan District, Wuhan, 430022, China. taozhangxh@hust.edu.cn.

Funding

Beijing Xisike Clinical Oncology Research Foundation Y-Q201802-039National Natural Science Foundation of China 82103385
6 · The paper itself

Abstract

backgroundFor gastric cancer patients, peritoneal metastasis poses a life-threatening risk due to the high incidence of treatment failure and disease recurrence. Conducting additional research aimed at identifying more efficacious strategies is imperative for enhancing treatment outcomes. This study examined the efficacy and safety of systemic chemotherapy plus a PD-1 inhibitor combination with intravenous or intraperitoneal bevacizumab for gastric cancer with peritoneal metastasis.

methodsWe conducted the open label, two-arm pilot study involved receiving albumin-bound paclitaxel (260 mg/m

resultsTen gastric cancer patients with peritoneal metastasis were enrolled in two arms (four in Arm A and six in Arm B) from August 19th, 2021 to June 1st, 2022. Until the end of the follow-up date, the mPFS for Arm A was 5.70 m (95% CI: 1.29-10.11), while Arm B had a mPFS of 9.07 m (95% CI: 3.79-14.35). The mOS for Arm A and Arm B was 8.43 (95% CI: 6.70-10.17) and 11.23 months (95% CI: 2.90-19.56). At least one common Grade 3/4 AE occurred in 25% of Arm A participants and 16.7% of Arm B patients.

conclusionsAlbumin-bound paclitaxel plus S-1 with a PD-1 inhibitor and intraperitoneal or intravenous bevacizumab was well tolerated in gastric cancer patients with peritoneal metastasis.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBevacizumabPeritoneal NeoplasmsStomach NeoplasmsAdministration, IntravenousAdultAgedAntibodies, Monoclonal, HumanizedDrug CombinationsFemaleHumansImmune Checkpoint InhibitorsMaleMiddle AgedOxonic AcidPaclitaxelAntibodies, Monoclonal, HumanizedBevacizumabDrug CombinationsImmune Checkpoint InhibitorsOxonic AcidPaclitaxelPDCD1 protein, humanProgrammed Cell Death 1 ReceptorS 1 (combination)sintilimabTegafurBevacizumabChemotherapyGastric cancerPeritoneal metastasisSintilimab

Identifiers

PMID40481442
PMCPMC12143064

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.